Krystal Biotech Announces Initial Results From Ongoing KYANITE-1 Study Of KB707; Observed 27% Objective Response Rate And 73% Disease Control Rate As Of Data Cut-Off On Dec. 6
Krystal Biotech Announces Initial Results From Ongoing KYANITE-1 Study Of KB707; Observed 27% Objective Response Rate And 73% Disease Control Rate As Of Data Cut-Off On Dec. 6
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.